Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (Q34650664)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial |
scientific article |
Statements
1 reference
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (English)
1 reference
Robert J Motzer
1 reference
Bernard Escudier
1 reference
Piotr Tomczak
1 reference
Thomas E Hutson
1 reference
M Dror Michaelson
1 reference
Sylvie Negrier
1 reference
Stephane Oudard
1 reference
Martin E Gore
1 reference
Jamal Tarazi
1 reference
Subramanian Hariharan
1 reference
Connie Chen
1 reference
Brad Rosbrook
1 reference
Sinil Kim
1 reference
Brian I Rini
1 reference
16 April 2013
1 reference
1 reference
Identifiers
1 reference